Corrigendum: Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates (Nature Medicine (2017) 23 (439-449) DOI: 10.1038/nm.4290);Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates

Nature Medicine

Volumn 23, Issue 4, 2017, Pages 439-449

  Wang, Pi Xiao ^a,b,c   Ji, Yan Xiao ^b,c   Zhang, Xiao Jing ^a,b,c   Zhao, Ling Ping ^b,c   Yan, Zhen Zhen ^b,c   Zhang, Peng ^b,c   Shen, Li Jun ^a,b,c   Yang, Xia ^b,c   Fang, Jing ^d   Tian, Song ^a,b,c   Zhu, Xue Yong ^a,b,c   Gong, Jun ^b,c   Zhang, Xin ^b,c   Wei, Qiao Fang ^a,b,c   Wang, Yong ^b   Li, Jing ^e   Wan, Lu ^e   Xie, Qingguo ^e   She, Zhi Gang ^a,b,c   Wang, Zhihua ^a,b,c   Huang, Zan ^b,c   Li, Hongliang ^a,b,c   more..

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

^c WUHAN UNIVERSITY   (China)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^e HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS SIGNAL REGULATING KINASE 1; FLICE INHIBITORY PROTEIN; HYDROGEN PEROXIDE; INTERLEUKIN 1BETA; INTERLEUKIN 6; JANUS KINASE 1; REACTIVE OXYGEN METABOLITE; UBIQUITIN PROTEIN LIGASE E3; GLUCOSE BLOOD LEVEL; STRESS ACTIVATED PROTEIN KINASE 1; TUMOR NECROSIS FACTOR;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; FATTY LIVER; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; INSULIN RESISTANCE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIMATE; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ADOLESCENT; ADULT; ANIMAL; BIOPSY; DEPENDOPARVOVIRUS; DIAGNOSTIC IMAGING; DIMERIZATION; ECHOGRAPHY; FEMALE; GENE TARGETING; GENE VECTOR; GENETICS; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LIVER; LIVER CELL; MACACA FASCICULARIS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; BIOPSY; BLOOD GLUCOSE; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; DEPENDOVIRUS; DIMERIZATION; FEMALE; GENE KNOCK-IN TECHNIQUES; GENETIC VECTORS; HEPATOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INSULIN RESISTANCE; INTERLEUKIN-6; LIVER; MACACA FASCICULARIS; MALE; MAP KINASE KINASE KINASE 5; MICE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 8; NON-ALCOHOLIC FATTY LIVER DISEASE; POSITRON-EMISSION TOMOGRAPHY; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; ULTRASONOGRAPHY; YOUNG ADULT;

EID: 85013177886     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1017-1241b     Document Type: Erratum

References (67)

1. Michelotti, G.A., Machado, M.V. & Diehl, A.M. NAFLD, NASH and liver cancer. Nat. Rev. Gastroenterol. Hepatol. 10, 656-665 (2013).
2. Byrne, C.D. & Targher, G. NAFLD: a multisystem disease. J. Hepatol. 62 (Suppl. 1), S47-S64 (2015).
3. Mittal, S. et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 14, 124-131 e1 (2016).
4. Zhang, H.J. et al. Effects of moderate and vigorous exercise on nonalcoholic fatty liver disease: a randomized clinical trial. JAMA Intern. Med. 176, 1074-1082 (2016).
5. Nascimbeni, F. et al. From NAFLD in clinical practice to answers from guidelines. J. Hepatol. 59, 859-871 (2013).
6. LaBrecque, D.R. et al. World Gastroenterology Organization global guidelines: nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 48, 467-473 (2014).
7. Yki-Järvinen, H. Nonalcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2, 901-910 (2014).
8. Czech, M.P. Obesity notches up fatty liver. Nat. Med. 19, 969-971 (2013).
9. Wang, W., Zhang, Y., Yang, L. & Li, H. The innate immune signaling in cancer and cardiometabolic diseases: friends or foes? Cancer Lett. 387, 46-60 (2017).
10. Zhang, X.J., Zhang, P. & Li, H. Interferon regulatory factor signaling in cardiometabolic diseases. Hypertension 66, 222-247 (2015).
11. The Institute of Model Animals of Wuhan University. China. Eur. Heart J. 37, 3257-3259 (2016).
12. Gehrke, N. et al. Acut organ failure following the loss of anti-apoptotic cellular FLICE-inhibitory protein involves activation of innate immune receptors. Cell Death Differ. 22, 826-837 (2015).
13. Xiao, J. et al. Cellular FLICE-inhibitory protein protects against cardiac remodeling after myocardial infarction. Basic Res. Cardiol. 107, 239 (2012).
14. Li, H. et al. Cellular FLICE-inhibitory protein protects against cardiac remodeling induced by angiotensin II in mice. Hypertension 56, 1109-1117 (2010).
15. Cha, S.I. et al. Compartmentalized expression of c-FLIP in lung tissues of patients with idiopathic pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 42, 140-148 (2010).
16. Monteleone, I. et al. A functional role of flip in conferring resistance of Crohn's disease lamina propria lymphocytes to FAS-mediated apoptosis. Gastroenterology 130, 389-397 (2006).
17. Esmailzadeh, S., Huang, Y., Su, M.W., Zhou, Y. & Jiang, X. BIN1 tumor suppressor regulates Fas-Fas ligand-mediated apoptosis through c-FLIP in cutaneous T cell lymphoma. Leukemia 29, 1402-1413 (2015).
18. Schattenberg, J.M. et al. Ablation of c-FLIP in hepatocytes enhances death-receptor-mediated apoptosis and toxic liver injury in vivo. J. Hepatol. 55, 1272-1280 (2011).
19. Kohl, T. et al. Diabetic liver injury from streptozotocin is regulated through the caspase-8 homolog cFLIP, involving activation of JNK2 and intrahepatic immunocompetent cells. Cell Death Dis. 4, e712 (2013).
20. Schattenberg, J.M. et al. Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP. Am. J. Physiol. Gastrointest. Liver Physiol. 303, G498-G506 (2012).
21. Browning, J.D. & Horton, J.D. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 114, 147-152 (2004).
22. Scorletti, E. & Byrne, C.D. Omega-3 fatty acids, hepatic lipid metabolism and nonalcoholic fatty liver disease. Annu. Rev. Nutr. 33, 231-248 (2013).
23. Houstis, N., Rosen, E.D. & Lander, E.S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440, 944-948 (2006).
24. Gao, D. et al. The effects of palmitate on hepatic insulin resistance are mediated by NADPH oxidase 3-derived reactive oxygen species through JNK and p38 MAPK pathways. J. Biol. Chem. 285, 29965-29973 (2010).
25. Li, M. et al. MicroRNA-223 ameliorates alcoholic liver injury by inhibiting the IL-6-p47phox oxidative stress pathway in neutrophils. Gut. http://dx.doi.org/10.1136/gutjnl-2016-311861 [Epub ahead of print] (2016).
26. Taylor, P.R. et al. Activation of neutrophils by autocrine IL-17A-IL-17RC interactions during fungal infection is regulated by IL-6, IL-23, ROR-γt and dectin-2. Nat. Immunol. 15, 143-151 (2014).
27. Kleiger, G. & Mayor, T. Perilous journey: a tour of the ubiquitin-proteasome system. Trends Cell Biol. 24, 352-359 (2014).
28. Chang, L. et al. The E3 ubiquitin ligase itch couples JNK activation to TNF-a-induced cell death by inducing c-FLIP(L) turnover. Cell 124, 601-613 (2006).
29. Kamata, H. et al. Reactive oxygen species promote TNF-a-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120, 649-661 (2005).
30. Tilg, H. & Moschen, A.R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52, 1836-1846 (2010).
31. Tilg, H. & Moschen, A.R. Insulin resistance, inflammation and nonalcoholic fatty liver disease. Trends Endocrinol. Metab. 19, 371-379 (2008).
32. Arthur, J.S. & Ley, S.C. Mitogen-activated protein kinases in innate immunity. Nat. Rev. Immunol. 13, 679-692 (2013).
33. Kyriakis, J.M. & Avruch, J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol. Rev. 92, 689-737 (2012).
34. Fujino, G. et al. Thioredoxin and TRAF family proteins regulate reactive-oxygen-species-dependent activation of ASK1 through reciprocal modulation of the N-terminal homophilic interaction of ASK1. Mol. Cell. Biol. 27, 8152-8163 (2007).
35. Ji, Y.X. et al. The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signaling. Nat. Commun. 7, 11267 (2016).
36. Nam, H.J. et al. Structure of adeno-associated virus serotype 8, a gene therapy vector. J. Virol. 81, 12260-12271 (2007).
37. Neuschwander-Tetri, B.A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for noncirrhotic, nonalcoholic steatohepatitis (FLINT): a multicenter, randomized, placebo-controlled trial. Lancet 385, 956-965 (2015).
38. Sanyal, A.J. et al. Pioglitazone, vitamin E or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362, 1675-1685 (2010).
39. Lavine, J.E. et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. J. Am. Med. Assoc. 305, 1659-1668 (2011).
40. Nobili, V. et al. Effect of vitamin E on aminotransferase levels and insulin resistance in children with nonalcoholic fatty liver disease. Aliment. Pharmacol. Ther. 24, 1553-1561 (2006).
41. Neuschwander-Tetri, B.A. Future treatments of NASH. Curr. Hepatol. Rep. 15, 125-133 (2016).
42. Musso, G., Cassader, M. & Gambino, R. Nonalcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat. Rev. Drug Discov. 15, 249-274 (2016).
43. Xiang, M. et al. Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance and hepatic steatosis. J. Hepatol. 64, 1365-1377 (2016).
44. Xie, L. et al. DKK3 expression in hepatocytes defines susceptibility to liver steatosis and obesity. J. Hepatol. 65, 113-124 (2016).
45. Lin, J.H., Zhang, J.J., Lin, S.L. & Chertow, G.M. Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease. Nephron 129, 29-33 (2015).
46. Liu, Y., Yin, G., Surapisitchat, J., Berk, B.C. & Min, W. Laminar flow inhibits TNF-induced ASK1 activation by preventing dissociation of ASK1 from its inhibitor 14-3-3. J. Clin. Invest. 107, 917-923 (2001).
47. Davis, R.J. Signal transduction by the JNK group of MAP kinases. Cell 103, 239-252 (2000).
48. Vernia, S. et al. The PPAR-a-FGF21 hormone axis contributes to metabolic regulation by the hepatic JNK signaling pathway. Cell Metab. 20, 512-525 (2014).
49. Aguirre, V. et al. Phosphorylation of Ser307 in insulin receptor substrate 1 blocks interactions with the insulin receptor and inhibits insulin action. J. Biol. Chem. 277, 1531-1537 (2002).
50. Schultze, S.M., Hemmings, B.A., Niessen, M. & Tschopp, O. PI3K-AKT, MAPK and AMPK signaling: protein kinases in glucose homeostasis. Expert Rev. Mol. Med. 14, e1 (2012).
51. Kodama, Y. & Brenner, D.A. c-Jun N-terminal kinase signaling in the pathogenesis of nonalcoholic fatty liver disease: multiple roles in multiple steps. Hepatology 49, 6-8 (2009).
52. Cazanave, S.C. et al. JNK1-dependent PUMA expression contributes to hepatocyte lipo-apoptosis. J. Biol. Chem. 284, 26591-26602 (2009).
53. Ratziu, V., Goodman, Z. & Sanyal, A. Current efforts and trends in the treatment of NASH. J. Hepatol. 62 (Suppl. 1), S65-S75 (2015).
54. Negash, A.A. & Gale, M. Jr. Hepatitis regulation by the inflammasome signaling pathway. Immunol. Rev. 265, 143-155 (2015).
55. Rotman, Y. & Sanyal, A.J. Current and upcoming pharmacotherapy for nonalcoholic fatty liver disease. Gut 66, 180-190 (2017).
56. Wree, A., Broderick, L., Canbay, A., Hoffman, H.M. & Feldstein, A.E. From NAFLD to NASH to cirrhosis - new insights into disease mechanisms. Nat. Rev. Gastroenterol. Hepatol. 10, 627-636 (2013).
57. Zhang, X. et al. Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone. Circulation 124, 77-86 (2011).
58. Kleiner, D.E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313-1321 (2005).
59. Wang, P.X. et al. Hepatocyte TRAF3 promotes liver steatosis and systemic insulin resistance through targeting TAK1-dependent signaling. Nat. Commun. 7, 10592 (2016).
60. Deng, K.Q. et al. Suppressor of IKK is an essential negative regulator of pathological cardiac hypertrophy. Nat. Commun. 7, 11432 (2016).
61. Kraus, D. et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature 508, 258-262 (2014).
62. Oh, D.Y. et al. A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. Nat. Med. 20, 942-947 (2014).
63. Wang, X.A. et al. Interferon regulatory factor 9 protects against hepatic insulin resistance and steatosis in male mice. Hepatology 58, 603-616 (2013).
64. Wang, X.A. et al. Interferon regulatory factor 3 constrains IKKß-NF-κB signaling to alleviate hepatic steatosis and insulin resistance. Hepatology 59, 870-885 (2014).
65. Sridhar, S. et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat. Med. 19, 1305-1312 (2013).
66. Straussman, R. et al. Tumor micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504 (2012).
67. Rudin, C.M. et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat. Genet. 44, 1111-1116 (2012).